Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data fro ...

Cassava Sciences Shares Lower Premarket on $40 Million Penalty to Settle Doctored Data Claims Global News Select Sep 27, 2024, 3:48:00 AM ...

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate ...

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

Cassava Sciences Inc receives Investment Bank Analyst Rating Update By Investing.com • Sep 06, 2022 ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug, which ...

Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...

SAVA SEC Filings Filing Type: Financials Cassava Sciences, Inc. (SAVA) - 10-Q - Quarterly Report SEC FilingsThu, May 08 1 Comment Cassava Sciences, Inc. (SAVA) - 10-K - Annual Report SEC ...

The rankings are conducted by a specialised online survey group passed in the New South Wales province in Australia, which ...

EVERY month, 33-year-old Happy Dismas loses up to four days of work due to debilitating menstrual bleeding caused by uterine ...